![Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology](https://media.americanpharmaceuticalreview.com/m/28/article/598684.jpg)
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership | American Pharmaceutical Review - The Review of American Pharmaceutical Business & Technology
![Teva Pharmaceuticals on Twitter: "Teva announces new ESG targets addressing two of today's greatest global crises, access to medicines and climate change. Targets are tied to our recent issuance of a $5 Teva Pharmaceuticals on Twitter: "Teva announces new ESG targets addressing two of today's greatest global crises, access to medicines and climate change. Targets are tied to our recent issuance of a $5](https://pbs.twimg.com/media/FDRw4gEXEA8YNN6.jpg:large)
Teva Pharmaceuticals on Twitter: "Teva announces new ESG targets addressing two of today's greatest global crises, access to medicines and climate change. Targets are tied to our recent issuance of a $5
![S&P Global Ratings affirms Teva Pharmaceutical Industries at "BB-" (Local Currency LT credit rating); outlook stable S&P Global Ratings affirms Teva Pharmaceutical Industries at "BB-" (Local Currency LT credit rating); outlook stable](https://data.cbonds.com/organisations_logos/13739/1506089713teva.png)
S&P Global Ratings affirms Teva Pharmaceutical Industries at "BB-" (Local Currency LT credit rating); outlook stable
![Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes | Business Wire Teva Announces Launch of $2,060,000,000 (Equivalent) Offering of Sustainability-Linked Senior Notes | Business Wire](https://mms.businesswire.com/media/20230226005205/en/739014/23/teva_RGB_JPEG.jpg)